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Summary Between 1980 and 1985, 914 patients with head and neck squamous cell carcinoma underwent lymph node dissection in our
institution. The prognostic value of clinical factors has already been reported (Mamelle et al, 1994, Am J Surg 168: 494-498). We present
here a comparison of biological characteristics of pharyngeal tumours in patients who developed distant metastasis and in patients without
metastasis, matched on tumour site, node site and size, and year of diagnosis. Tumour differentiation, keratinization, vascular emboli,
immunohistochemical expression of p53, c-erb-B2, Rb and bc12 were first assessed in 31 pairs of patients. Factors of potential interest were
then determined in 32 additional pairs of patients. Statistical analysis showed that the risk of distant metastasis was halved in patients with
tumours expressing c-erb-B2 compared with patients with c-erb-B2-negative tumours (P= 0.05). The significance of c-erb-B2 expression and
its potential value as a prognostic factor is discussed.
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The unpredictable clinical behaviour of head and neck squamous
cell carcinomas (HNSCC) has led many investigators to search for
biological factors that may be used as a prognostic index. In a
previous paper, we reported on the prognostic value ofclinical and
anatomical factors in 914 patients who underwent neck surgery at
the Gustave-Roussy Institute. The size ofthe nodes and their level
in the neck were shown to be the best clinical factors predictive of
distant metastasis (Mamelle et al, 1994). In the present study, we
used the same series ofpatients to determine whether histobiolog-
ical characteristics of biopsy specimens obtained from primaries
could provide additional information to complete these clinical
prognostic factors. We were particularly interested in biological
factors capable of predicting distant metastasis, as this is a major
cause of death in patients with pharyngeal tumours who already
undergo aggressive locoregional treatment (Mamelle et al, 1994).
Three histological characteristics and the expression of four
proteins were selected for evaluation as they were considered to be
of prognostic value in different tumour types and were technically
evaluable on tumour biopsy specimens. Histological grading,
keratinization and vascular emboli have a recognized prognostic
value in many tumours and have been linked to distant metastasis
in HNSCC (Roland et al, 1992; Janot et al, 1996). p53 gene muta-
tion is one of the most common genetic alterations in HNSCC
(Ahomadegbe et al, 1995) and is associated with overexpression of
p53 protein, but its prognostic significance is controversial in
HNSCC (Bourhis et al, 1994; Ahomadegbe et al, 1995; Shin et al,
1996). The c-erb-B2 oncoprotein is a transmembrane protein
whose presence has been associated with a poor prognosis in
several human neoplasms (Slamon et al, 1987; Mizutani et al,
1993). The retinoblastoma (Rb) gene was the first tumour-
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suppressor gene to have been identified; a loss of expression,
observed in a small subset of HNSCC (Yoo et al, 1994), is a prog-
nostic factor in certain tumour types (Logothetis et al, 1992). The
bc12 gene is implicated in apoptosis and its hyperexpression is
thought to have a prognostic impact in some squamous cell carci-
nomas (Pezzella et al, 1993).
As the tumour site, nodal involvement and the type of treatment
are very strongly linked to the prognosis of HNSCC, we used a
matched case-control design. Each patient who developed a
distant metastasis was matched to a control patient with the same
tumour site, the same nodal size and level in the neck, and with a
follow-up at least equal to the time between treatment of the
primary tumour and the diagnosis of metastasis in the case, but
free of distant metastasis at the end of that time. With such a
design, patients with the same clinical prognostic characteristics
and particularly with identical clinical nodal involvement could be
compared. During the first part ofthe study, all the histobiological
factors mentioned above were tested in a small series of patients
and two of them were found to be of potential prognostic value.
During the second part of the study, these two factors were evalu-
ated in a larger population of patients, using the same statistical
methodology.
MATERIALS AND METHODS
Patient population
Between 1980 and 1985, 914 patients with HNSCC underwent
lymph node dissection at our institute. The primary tumour site
was the oral cavity (287), hypopharynx (249), larynx (247) and
oropharynx (131). The treatment was standardized for each site.
Among the clinical factors studied in multivariate analysis, the
location ofthe lymph node (upper, middle, lower neck) and its size
were found to significantly predict the risk of distant metastasis
and overall survival (Mamelle et al, 1994).
The first part of the study included patients with an oropharyn-
geal tumour: 40 of the 131 patients with oropharyngeal tumours
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Table 1 Initial tumour characteristics
Oropharynx Hypopharynx Total
Metastasis No metastasis Metastasis No metastasis Metastasis No metastasis
(31) (31) (32) (32) (63) (63)
Ta
Ti 1 2 0 0 1 2
T2 11 9 4 3 15 12
T3 18 18 25. 26 43 44
T4 1 2 3 3 4 5
Na
NO 11 11 7 7 18 18
Ni 3 3 8 8 11 11
N2 14 14 14 14 28 28
N3 3 3 3 3 6 6
Node location
None 11 11 7 7 18 18
Upperneck 13 13 15 15 28 28
Middle neck 5 6 5 5 10 11
Lowerneck 2 1 5 5 7 6
aUICC classification.
developed distant metastases and in 31 of these 40 patients with
metastasis, paraffin blocks of biopsy specimens of their primary
tumour were available for immunohistochemistry. Each of these
31 patients was matched with a control patient with an oropharyn-
geal tumour who had the largest lymph node of a similar size and
location, the same year of treatment and no metastasis after a
follow-up at least equal to the time between the treatment of the
primary tumour of the case and the diagnosis of the metastasis.
When several control cases were available, we chose the patient
who had the treatment period closest to that ofthe case presenting
metastasis. Seven histobiological factors were tested in these 31
pairs of matched cases and control patients.
In the second part of the study, the two most prognostic
immunohistochemical factors were evaluated in a larger series of
patients. Of a series of249 patients with hypopharyngeal tumours,
92 developed distant metastasis. Thirty-two of these 92 patients
were chosen randomly and matched with patients with hypopha-
ryngeal tumours, who had lymph nodes ofthe same size and loca-
tion and the same year oftreatment, but were free ofmetastasis.
Histological parameters
The original biopsy specimen of each patient was first reviewed
for quality control to confirm the diagnosis (squamous cell carci-
noma) and to assess the quality ofthe specimen. Tumour differen-
tiation (poor, moderate, high) based on Broders' classification
(Broders, 1926) and the presence or absence of keratinization and
of vascular emboli were determined.
Immunohistochemical staining was carried out on paraffin
sections, using the labelled streptavidin-biotin method (LSAB,
K675, Dako; Hsu et al, 1981) with appropriate positive and nega-
tive controls. The primary antibodies used were:
* p53 (DO7, 1:25; Dako). Staining was nuclear and cases were
considered significant when the nuclei of more than 5% of
tumour cells exhibited strong staining.
* c-erb-B2 (DA485, 1:100; Dako). Staining targeted the
membrane but some spread to the cytoplasm. Only cases
exhibiting strong membrane staining in more than 5% of
tumour cells were regarded as significant.
* Rb (C-15, 1:100; Santa-Cruz). Staining was nuclear and quan-
tified as absent or present.
* bcl2 (M887, 1:10; Dako). Staining was intracytoplasmic and
only cases with more than 5% of stained tumour cells were
regarded as significant.
Weak staining in less than 5% of tumour cells was considered
non-significant.
Statistical methods
An exact conditional logistic regression method performed with
LogXact (Mehta and Patel, 1995) was used for the analysis. The
P-values presented correspond to exact-score tests.
RESULTS
First part of the study
The seven histobiological parameters, namely differentiation and
keratinization of the tumour, the presence of vascular emboli and
immunohistochemical expression of p53, c-erb-B2, Rb and bcl2
were first evaluated in a series of31 matched pairs ofpatients with
oropharyngeal tumours. The 31 cases with metastatic disease and
the 31 matched controls had nodes that were similar in size and at
the same level (Table 1). They had also received their first treat-
ment during the same year.
Only two histobiological factors, p53 and c-erb-B2, stood out as
being of potential prognostic significance in the univariate and
multivariate analyses: among 31 pairs, p53 expression was detected
in 19 cases with metastasis and in 13 control cases (OR = 2). c-erb-
B2 expression was positive in eight cases with metastasis and in 15
control cases (OR = 0.46). Results were not statistically significant
in the 31 pairs ofpatients (Table 2).
Second part of the study
Given the results of the first part of the study, 32 pairs of patients
with hypopharyngeal tumours were added to the series of 31 pairs
of patients with oropharyngeal tumours. The entire population
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Table 2 Prognostic value of histobiological factors in oropharyngeal cancer: 31 cases with metastasis and 31 controls
Factor Case/control ORla p OR2b P
p53
Negative 12/18 1 1
Positive 19/13 2 0.24 2.16 0.18
c-erb-B2
Negative 23/16 1 1
Positive 8/15 0.46 0.17 0.46 0.18
Rb
Negative 6/5 1
Positive 25/26 0.58 1.00
bc12
Negative 29/27 1
Positive 2/4 0.5 0.69
Differentiationc
WD 3/3 1
MD 18/20 0.95
PD 10/8 1.31 0.93
Keratinization
No 13/11 1
Yes 18/20 0.78 0.80
Emboli
No 26/27 1
Yes 5/4 1.25 1.00
aUnivariate analysis. bMultivariate analysis taking into account the other factor. cWD, well differentiated; MD, moderately
differentiated; PD, poorly differentiated.
included, therefore, 63 cases with metastasis and 63 controls, and
was tested for p53 and c-erb-B2 expression.
The 63 cases with metastasis and the 63 matched controls had
similar T stages, the same sized nodes and a similar node location
(Table 1). They were also treated during the same year. Among the
63 pairs, p53 expression was detected in 35 cases with metastasis
and in 26 control cases (OR = 1.7, P = 0.20). The risk ofmetastasis
was found to be halved in patients with tumours expressing c-erb-
B2 compared with other patients: among 62 pairs, c-erb-B2
expression was positive in 22 cases with metastasis and in 35
control cases (OR = 0.48, P = 0.047; Table 3).
DISCUSSION
It is difficult to determine biological prognostic factors in HNSCC
because these tumours are clinically heterogeneous. The biological
factors synonymous with tumour aggressiveness are often associ-
ated with clinical prognostic factors, such as the tumour site or
nodal involvement. Ascertaining whether biological factors really
provide novel prognostic information and that they are not simply
a reflection ofthe weight ofclinical factors is an arduous task.
This case-control study compared the biological characteristics
ofpatients who developed distant metastases with those ofpatients
with a similar tumour site, node size and level, who never devel-
oped metastasis. The statistical methodology was feasible as we
had at our disposal a large series of 914 patients who had under-
gone neck surgery in our institution (Mamelle et al, 1994). Patients
with metastasis were matched with their metastasis-free counter-
parts who had the same clinical prognostic factors and the same
treatment. A previous study conducted by us had shown that the
node size and level in the neck were the factors that best predicted
Table 3 Multivariate analysis of biological factors in oropharyngeal and
hypopharyngeal tumours: 63 cases with metastasis and 63 controls
Factor Case/control OR P
p53
Negative 28/37 1
Positive 35/26 1.7 0.18
c-erb-B2a
Negative 40/27 1
Positive 22/35 0.48 0.047
aln 1 out of 63 pairs, c-erb-B2 expression was not evaluated.
metastases. When the statistical methodology was used to analyse
the biological factors selected, histological grading, including
differentiation and keratinization, and the presence or absence of
vascular emboli detected in biopsy specimens of the primary
tumour as well as immunohistochemical expression ofRb and bc12
were not found to be predictive of distant metastasis. Only two
factors appeared to be potentially of prognostic import, namely
p53 and c-erb-B2 immunohistochemical expression.
The clinical significance of p53 mutations and expression is
currently being investigated in HNSCC. Some studies have noted the
absence of a significant correlation between p53 accumulation and
clinical outcome (Somers et al, 1992; Bourhis et al, 1994;
Ahomadegbe et al, 1995). In a recent paper, Shin et al (1996) found
that p53 expression was associated with an increased risk of second
primaries and locoregional failures but not with distant metastasis. In
our study, the risk of distant metastasis was multiplied by 1.7 in
patients with p53 hyperexpression, but this result was not statistically
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significant. With 63 pairs of patients, this study had an 80% chance
ofdetecting a relative risk of2.7 and 95% chance ofdetecting a rela-
tive risk of 3.5. Our results confirm that p53 expression is not a
strong prognostic factor for distant metastasis in HNSCC.
The main finding in this case-control study was unexpected: c-
erb-B2 immunohistochemical expression was significantly associ-
ated with a decreased risk of distant metastases in patients with
pharyngeal tumours. This result was initially obtained in the group
of patients with oropharyngeal tumours and was confirmed in the
group ofpatients with hypopharyngeal tumours. As immunohisto-
chemical assessment of specimens is rapid, c-erb-B2 expression
could be used in routine practice as a biological prognostic tool. It
should be emphasized that the interpretation of immunohisto-
chemical analyses is dependent on the quality of the technique
(quality of specimen, fixative and sensitivity of c-erb-B2 anti-
bodies) and that quantification of c-erb-B2 expression is contin-
gent on the experience of the pathologist. A polyclonal antibody
(DA 485) was used in this study because it had already been tried
and tested in our institution in breast cancer (Terrier et al, 1996)
and because its sensitivity and specificity had been favourably
evaluated in other studies (Press et al, 1994). Membrane staining
was only considered because the c-erb-B2 gene product is
normally localized in the cell membrane. Cytoplasmic staining in
the absence of membrane staining was rare and considered to be
non-specific (Craven et al, 1992).
c-erb-B2 amplification and overexpression has been correlated
with a shorter surivival in breast cancer (Slamon et al, 1987; Press
et al, 1994), yet some reports state that c-erb-B2 is oflimited prog-
nostic value, if any (Van de Vijvers, 1988; Zhou, 1989). The prog-
nostic value of c-erb-B2 has not been extensively studied in
HNSCC patients. The studies that included patients with tumours
ofdifferent sites and stages found no correlation between c-erb-B2
expression and survival (Craven et al, 1992; Field et al, 1992).
Inconsistent with our results, a recent paper reported a correlation
between c-erb-B2 overexpression and poor survival in 39 patients
presenting SCC of the oral cavity (Xia et al, 1997). There are,
however, many differences between their paper and ours. First, the
prognostic value ofc-erb-B2 in Xia's paper can be attributed to its
relation with clinical factors (nodal involvement, distant metas-
tases at initial presentation). In our work, we compared the occur-
rence of distant metastases in patients with similar clinical
features. Second, Xia et al studied oral SCC and our study only
included pharyngeal tumours. C-erb-B2 overexpression may, as
suggested by Xia et al, be a characteristic of oral SCC and not of
other HNSCC.
c-erb-B2 oncogene abnormalities, including gene amplification
and overexpression are a critical event in carcinogenesis in breast
tissue. In contrast, c-erb-B2 alterations have never been found at
the DNA level in HNSCC, nor has gene activation been proven
during HNSCC carcinogenesis (Riviere et al, 1991). Kilpi et al
(1995) have compared c-erb-B2 immunohistochemical expression
in normal oral mucosa, lichen planus and subsequent squamous
cell carcinoma: c-erb-B2 was more frequently expressed in normal
mucosa than in tumours. In a small series of patients with pharyn-
geal carcinoma, we also compared the immunohistochemical
expression of c-erb-B2 in tumour with that of non-transformed
mucosa surrounding the tumour and obtained similar results.
These data suggest that the loss ofc-erb-B2 expression, at least in
a subset of HNSCC, is a step in the process of tumorigenesis. The
combined activity of different oncogenes and loss of activity of
tumour-suppressor genes are a prerequisite for the carcinogenic
process. A quantitative or qualitative modification in c-erb-B2
expression could be accompanied by activation of other onco-
genes. c-erb-B2 and the epidermal growth factor receptor (EGFR)
are, to a high degree, homologous and these proteins interact in
concert to increase mitogenic signal transduction (Dougall et al,
1993). In human skin (Maguire et al, 1989) and in human renal cell
carcinoma (Weidner et al, 1990), c-erb-B2 and EGFR have been
shown to exhibit an inverse relationship. In human breast cancer,
using a sensitive radioimmunohistochemical assay, Robertson et al
(1996) have shown an inverse relationship between EGFR and c-
erb-B2 expression, which is disrupted by c-erb-B2 amplification.
For a better understanding of the biology of HNSCC, further
investigations are warranted on combined alterations of these
proteins andlor other oncogenes.
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